MAIA Biotechnology Financials
| MAIA Stock | USD 2.15 0.08 3.59% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.46 | 1.5321 |
|
|
The financial analysis of MAIA Biotechnology is a critical element in measuring its lifeblood. Investors should not minimize MAIA Biotechnology's ability to pay suppliers or employees on time, ensuring interest payments are not accumulating.
Net Income |
|
MAIA | Select Account or Indicator |
Understanding current and past MAIA Biotechnology Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of MAIA Biotechnology's financial statements are interrelated, with each one affecting the others. For example, an increase in MAIA Biotechnology's assets may result in an increase in income on the income statement.
Please note, the presentation of MAIA Biotechnology's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, MAIA Biotechnology's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of MAIA Biotechnology's management manipulating its earnings.
MAIA Biotechnology Stock Summary
MAIA Biotechnology competes with Lineage Cell, Armata Pharmaceuticals, Portage Biotech, Larimar Therapeutics, and Lyra Therapeutics. MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer, primarily non-small cell lung cancer. The company was founded in 2018 and is headquartered in Chicago, Illinois. Maia Biotechnology operates under Biotechnology classification in the United States and is traded on AMEX Exchange. It employs 9 people.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | USA Stock View All |
| Exchange | NYSE MKT Exchange |
| CUSIP | 552641102 |
| Location | Illinois; U.S.A |
| Business Address | 444 West Lake |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | maiabiotech.com |
| Phone | 312 416 8592 |
| Currency | USD - US Dollar |
MAIA Biotechnology Key Financial Ratios
| Return On Equity | -5.6 | ||||
| EBITDA | (20.18 M) | ||||
| Net Income | (19.77 M) | ||||
| Cash Per Share | 0.75 X | ||||
| Current Ratio | 2.78 X |
MAIA Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining MAIA Biotechnology's current stock value. Our valuation model uses many indicators to compare MAIA Biotechnology value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across MAIA Biotechnology competition to find correlations between indicators driving MAIA Biotechnology's intrinsic value. More Info.MAIA Biotechnology is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At present, MAIA Biotechnology's Return On Equity is projected to decrease significantly based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the MAIA Biotechnology's earnings, one of the primary drivers of an investment's value.MAIA Biotechnology Systematic Risk
MAIA Biotechnology's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. MAIA Biotechnology volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was thirty-six with a total number of output elements of twenty-five. The Beta measures systematic risk based on how returns on MAIA Biotechnology correlated with the market. If Beta is less than 0 MAIA Biotechnology generally moves in the opposite direction as compared to the market. If MAIA Biotechnology Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one MAIA Biotechnology is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of MAIA Biotechnology is generally in the same direction as the market. If Beta > 1 MAIA Biotechnology moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in MAIA Biotechnology Stock are looking for potential investment opportunities by analyzing not only static indicators but also various MAIA Biotechnology's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of MAIA Biotechnology growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
MAIA Biotechnology November 22, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of MAIA Biotechnology help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of MAIA Biotechnology. We use our internally-developed statistical techniques to arrive at the intrinsic value of MAIA Biotechnology based on widely used predictive technical indicators. In general, we focus on analyzing MAIA Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build MAIA Biotechnology's daily price indicators and compare them against related drivers.
| Information Ratio | (0.09) | |||
| Maximum Drawdown | 28.1 | |||
| Value At Risk | (9.23) | |||
| Potential Upside | 8.37 |
Complementary Tools for MAIA Stock analysis
When running MAIA Biotechnology's price analysis, check to measure MAIA Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MAIA Biotechnology is operating at the current time. Most of MAIA Biotechnology's value examination focuses on studying past and present price action to predict the probability of MAIA Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MAIA Biotechnology's price. Additionally, you may evaluate how the addition of MAIA Biotechnology to your portfolios can decrease your overall portfolio volatility.
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios |